Pernicious Anemia Diagnosis And Treatment Market Report 2026

Pernicious Anemia Diagnosis And Treatment Market Overview

• Pernicious Anemia Diagnosis And Treatment market size has reached to $1.51 billion in 2025 • Expected to grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Prevalence Of Vitamin B12 Deficiency Fueling Growth In The Market Due To Shifting Dietary Patterns And Aging Population • Market Trend: Advancements In B12 Maintenance Therapy To Enhance Patient Adherence And Outcomes • North America was the largest region in 2025.

What Is Covered Under Pernicious Anemia Diagnosis And Treatment Market?

Pernicious anemia diagnosis and treatment refers to the process of identifying and managing a condition where the body cannot produce enough healthy red blood cells due to impaired absorption of vitamin B12, often linked to the absence of intrinsic factor. Diagnosis involves assessing clinical symptoms such as fatigue, weakness, and neurological disturbances. Treatment focuses on restoring vitamin B12 levels to promote normal red blood cell production, relieve symptoms, and prevent long-term health complications. The main types of pernicious anemia diagnosis and treatment include complete blood count tests, vitamin B12 deficiency tests, and intrinsic factor deficiency tests. A complete blood count (CBC) test is a common blood test that measures various components of the blood, and it can help to identify abnormal levels of red blood cells and hemoglobin, which are often indicators of anemia, and can assist in diagnosing the condition. Different types of treatments are offered, including vitamin B12 injections, vitamin B12 pills, and a spray, which are administered through different routes such as injection, oral, and intranasal. It is utilized by end users, including hospitals, clinics, diagnostic centers, and others.

What Is The Pernicious Anemia Diagnosis And Treatment Market Growth Forecast?

The pernicious anemia diagnosis and treatment market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in safety iv catheter technologies, increasing adoption of smart and antimicrobial catheters, expansion of home healthcare services, rising preference for integrated/closed iv systems, growing demand for minimally invasive therapy administration. Major trends in the forecast period include increasing adoption of ai-based catheter insertion guidance systems, rising use of cloud-based patient monitoring for iv therapy, growing development of antimicrobial and smart catheters, increasing integration of iot-enabled devices for iv monitoring, rising implementation of smart manufacturing for peripheral iv catheters.

Global Pernicious Anemia Diagnosis And Treatment Market Segmentation

1) By Type: Complete Blood Count Test, Vitamin B12 Deficiency test, Intrinsic Factor Deficiency Test 2) By Treatment: Vitamin B12 Injections, Vitamin B12 Pills, Spray 3) By Route Of Administration: Injection, Oral, Intranasal 4) By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-users Subsegments: 1) By Complete Blood Count (CBC) Test: Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume (MCV), White Blood Cell Count, Platelet Count 2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test, Methylmalonic Acid (MMA) Test, Homocysteine Test, Holotranscobalamin (Active B12) Test 3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test, Parietal Cell Antibody Test, Schilling Test, Gastrin Level Test

What Is The Driver Of The Pernicious Anemia Diagnosis And Treatment Market?

The rising prevalence of vitamin B12 deficiency is expected to drive growth in the pernicious anemia diagnosis and treatment market going forward. Vitamin B12 deficiency occurs when the body lacks enough of the vitamin to produce adequate red blood cells, leading to symptoms such as fatigue, weakness, and neurological issues. Vitamin B12 deficiency is rising due to the increasing adoption of plant-based diets, which often lack sufficient natural sources of B12 and can lead to inadequate intake without proper supplementation. Vitamin B12 deficiency supports pernicious anemia diagnosis and treatment as low B12 levels directly impair red blood cell production, guiding doctors to administer B12 supplementation as a primary and effective treatment strategy. For instance, in February 2023, according to a report published by the National Health Service (NHS), a UK-based government health organization, both vitamin B12 and folate deficiencies are more prevalent in older adults, affecting roughly 1 in 10 individuals 75 years of age or older and 1 in 20 of those 65 to 74 years of age. Therefore, the rising prevalence of vitamin B12 deficiency is driving growth in the pernicious anemia diagnosis and treatment industry.

Key Players In The Global Pernicious Anemia Diagnosis And Treatment Market

Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc., Merck KGaA, Abbott Laboratories, Siemens Healthineers AG, Ortho Clinical Diagnostics Inc., Quest Diagnostics Incorporated, Bio-Techne Corporation

Global Pernicious Anemia Diagnosis And Treatment Market Trends and Insights

Major companies operating in the pernicious anemia diagnosis and treatment market are focusing on developing innovative solutions, such as vitamin B12 maintenance therapy solutions, to improve patient adherence and long-term disease management. Vitamin B12 maintenance therapy solutions involve regular, ongoing supplementation through oral tablets, injections, or nasal sprays to sustain adequate B12 levels and prevent recurrence of deficiency-related symptoms. For instance, in February 2024, Lupin Pharmaceuticals Inc., an India-based pharmaceutical company, launched cyanocobalamin nasal spray, 500 mcg/spray, a non-invasive alternative for vitamin B12 supplementation. This nasal spray provides a convenient and effective method for patients with pernicious anemia who struggle with oral vitamin B12 forms. It helps improve B12 absorption and supports the management of vitamin B12 deficiency, ultimately enhancing patient compliance and treatment outcomes.

What Are Latest Mergers And Acquisitions In The Pernicious Anemia Diagnosis And Treatment Market?

In February 2025, Lightstone Group, a US-based investment firm, acquired Pfizer’s Durham facility for $41.1 million. The acquisition of this property provided a unique opportunity to add a move-in-ready, state-of-the-art clinical supply cGMP facility, designed for the highest quality standards, to the growing portfolio. Pfizer Inc. is a US-based manufacturer of vitamin B12 capsules for pernicious anemia treatment.

Regional Outlook

North America was the largest region in the pernicious anemia diagnosis and treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pernicious Anemia Diagnosis And Treatment Market?

The pernicious anemia diagnosis and treatment market consists of revenues earned by entities by providing services such as antibody testing, neurological evaluation services, nutritional counseling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pernicious anemia diagnosis and treatment market also includes sales of methylcobalamin supplements, combination supplements, and anemia management trackers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pernicious Anemia Diagnosis And Treatment Market Report 2026?

The pernicious anemia diagnosis and treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pernicious anemia diagnosis and treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.